Profile data is unavailable for this security.
About the company
Clene Inc. is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease, and multiple sclerosis. It specializes in the discovery, development, and commercialization of clean-surfaced nanotechnology (CSN) therapeutics. CNM-Au8, the lead asset, is a concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. CNM-Au8’s mechanism of action targets mitochondrial dysfunction by catalyzing the production of nicotinamide adenine dinucleotide. Its CNM-ZnAg is a broad-spectrum antiviral, antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions under development to treat infectious disease and to provide immune support for symptom resolution. Its CNM-AgZn17 is a gel polymer suspension of Zn2+ and Ag+ under development for the treatment of infectious diseases and to support wound healing.
- Revenue in USD (TTM)214.00k
- Net income in USD-30.50m
- Incorporated2020
- Employees75.00
- LocationClene Inc6550 South Millrock Drive, Suite G50SALT LAKE CITY 84121United StatesUSA
- Phone+1 (801) 676-9695
- Fax+1 (302) 531-3150
- Websitehttps://clene.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| INmune Bio Inc | 50.00k | -49.89m | 37.75m | 22.00 | -- | 1.49 | -- | 755.02 | -2.14 | -2.14 | 0.0021 | 0.9546 | 0.0012 | -- | 0.0258 | 2,272.73 | -115.83 | -45.54 | -153.59 | -52.16 | -- | -- | -99,774.00 | -19,298.45 | -- | -942.22 | 0.00 | -- | -90.97 | -- | -40.24 | -- | -- | -- |
| Generation Bio Inc | 15.27m | -62.63m | 38.68m | 115.00 | -- | 0.7647 | -- | 2.53 | -9.35 | -9.35 | 2.28 | 7.51 | 0.0824 | -- | 11.73 | 132,782.60 | -33.79 | -35.85 | -39.21 | -38.42 | -- | -- | -410.13 | -2,304.98 | -- | -- | 0.00 | -- | 236.92 | -- | -3.99 | -- | -34.55 | -- |
| Aligos Therapeutics Inc | 2.65m | -86.46m | 39.94m | 70.00 | -- | 0.556 | -- | 15.09 | -12.70 | -12.70 | 0.2964 | 11.67 | 0.0267 | -- | -- | 37,800.00 | -87.25 | -60.83 | -111.39 | -72.31 | -- | -- | -3,267.65 | -1,462.14 | -- | -- | 0.002 | -- | -74.60 | -- | -49.65 | -- | -45.83 | -- |
| Lisata Therapeutics Inc | 1.07m | -18.24m | 40.58m | 26.00 | -- | 2.32 | -- | 37.92 | -2.13 | -2.13 | 0.1246 | 1.98 | 0.0357 | -- | -- | 41,153.85 | -60.85 | -44.77 | -71.25 | -49.07 | -- | -- | -1,704.86 | -13,065.70 | -- | -- | 0.00 | -- | -- | -- | 4.10 | -- | -- | -- |
| CEL-SCI Corp | 0.00 | -25.41m | 41.20m | 43.00 | -- | 2.46 | -- | -- | -7.81 | -7.81 | 0.00 | 1.99 | 0.00 | -- | -- | -- | -92.16 | -72.20 | -111.94 | -80.91 | -- | -- | -- | -- | 2.20 | -38.20 | 0.3328 | -- | -- | -- | 7.86 | -- | -57.33 | -- |
| ABVC Biopharma Inc | 797.92k | -4.12m | 41.28m | 16.00 | -- | 3.21 | -- | 51.74 | -0.2223 | -0.2223 | 0.0464 | 0.4985 | 0.0448 | -- | 0.408 | 49,870.00 | -24.89 | -105.17 | -42.73 | -217.00 | 0.2469 | 75.19 | -555.90 | -2,124.21 | 0.6241 | -13.71 | 0.0662 | -- | 234.31 | -6.20 | 37.05 | -- | -- | -- |
| Clene Inc | 214.00k | -30.50m | 42.53m | 75.00 | -- | -- | -- | 198.75 | -3.33 | -3.33 | 0.0231 | -1.21 | 0.0079 | 0.4021 | 0.475 | 2,853.33 | -113.20 | -55.54 | -280.47 | -72.66 | 82.24 | 76.19 | -14,250.47 | -6,165.10 | 1.52 | -8.71 | 3.64 | -- | -47.71 | -- | 20.41 | -- | -- | -- |
| CervoMed Inc | 6.16m | -25.58m | 42.56m | 15.00 | -- | 1.64 | -- | 6.91 | -2.87 | -2.87 | 0.6919 | 2.81 | 0.155 | -- | 7.58 | 410,652.00 | -64.37 | -54.89 | -71.42 | -60.99 | -- | -- | -415.36 | -428.45 | -- | -- | 0.00 | -- | 36.29 | -- | -650.08 | -- | -- | -- |
| Lipocine Inc | 4.32m | -5.48m | 42.86m | 16.00 | -- | 2.96 | -- | 9.92 | -1.04 | -1.04 | 0.7933 | 2.61 | 0.2351 | -- | 41.82 | 270,168.10 | -29.78 | -30.54 | -32.92 | -34.86 | -- | -- | -126.66 | -194.90 | -- | -- | 0.00 | -- | 492.80 | 132.45 | 100.05 | -- | -- | -- |
| Plus Therapeutics Inc (USA) | 5.26m | -20.58m | 43.11m | 21.00 | -- | 6.09 | -- | 8.20 | -1.71 | -1.71 | 0.062 | 0.0384 | 0.41 | -- | -- | 250,381.00 | -160.45 | -80.94 | -- | -211.40 | -- | -- | -391.33 | -605.55 | -- | -2.19 | 0.00 | -- | 18.54 | -3.61 | 2.54 | -- | 59.47 | -- |
| Kezar Life Sciences Inc | 0.00 | -61.71m | 44.16m | 55.00 | -- | 0.5322 | -- | -- | -8.44 | -8.44 | 0.00 | 11.33 | 0.00 | -- | -- | 0.00 | -47.14 | -34.75 | -54.13 | -36.82 | -- | -- | -- | -5,003.10 | -- | -- | 0.0742 | -- | -100.00 | -- | 17.80 | -- | -45.57 | -- |
| OS Therapies Inc | 0.00 | -20.26m | 44.72m | 4.00 | -- | 11.62 | -- | -- | -0.9794 | -0.9794 | 0.00 | 0.1415 | 0.00 | -- | -- | 0.00 | -334.55 | -- | -870.52 | -- | -- | -- | -- | -- | -- | -2,674.49 | 0.00 | -- | -- | -- | -37.51 | -- | -- | -- |
| Atossa Therapeutics Inc | 0.00 | -30.18m | 45.90m | 13.00 | -- | 0.922 | -- | -- | -3.52 | -3.52 | 0.00 | 5.78 | 0.00 | -- | -- | 0.00 | -43.90 | -26.93 | -48.89 | -29.04 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 15.25 | -- | 20.02 | -- |
| UMeWorld Inc | 7.93k | -1.32m | 47.06m | 1.00 | -- | -- | -- | 5,934.66 | -0.0148 | -0.0148 | 0.00009 | -0.0477 | 0.1253 | -- | 1.71 | 7,930.00 | -2,066.65 | -273.32 | -- | -- | -285.62 | -768.98 | -16,497.98 | -13,102.00 | -- | -2.36 | -- | -- | 136.17 | -- | -15.02 | -- | -- | -- |
| NRX Pharmaceuticals Inc | 242.00k | -38.06m | 47.20m | 2.00 | -- | -- | -- | 195.06 | -2.32 | -2.32 | 0.0141 | -0.9304 | 0.0249 | -- | -- | -- | -391.21 | -210.73 | -- | -603.16 | 59.92 | -- | -15,727.69 | -- | -- | -- | -- | -- | -- | -- | 16.69 | -- | -- | -- |
| Mira Pharmaceuticals Inc | 0.00 | -28.42m | 47.32m | -- | -- | 5.91 | -- | -- | -1.52 | -1.52 | 0.00 | 0.1911 | 0.00 | -- | -- | -- | -115.28 | -- | -123.33 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 34.46 | -- | -- | -- |
Data as of Feb 06 2026. Currency figures normalised to Clene Inc's reporting currency: US Dollar USD
6.97%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Scoggin Management LPas of 30 Sep 2025 | 250.00k | 2.42% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 173.59k | 1.68% |
| Geode Capital Management LLCas of 30 Sep 2025 | 75.99k | 0.74% |
| Lunt Capital Management, Inc.as of 31 Dec 2025 | 52.26k | 0.51% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 43.72k | 0.42% |
| Parsons Capital Management, Inc.as of 31 Dec 2025 | 37.24k | 0.36% |
| Renaissance Technologies LLCas of 30 Sep 2025 | 30.44k | 0.30% |
| Marshall Wace LLPas of 30 Sep 2025 | 22.71k | 0.22% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Sep 2025 | 17.53k | 0.17% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2025 | 16.80k | 0.16% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
